TORONTO, Oct. 10, 2018 — Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company) announces the Company’s achievement of yet another international milestone as part of its global expansion plan: The Company has now exported THC distillate within a stability range that meets the standards suitable for product commercialization to Switzerland.
The Company has developed the process for distillation of cannabis resin for future commercial production of purified cannabis concentrates and their use in various cannabis products. Extraction and distillation was completed at Wayland’s facilities in Langton Ontario, Canada.
“This is the second country where we have successfully exported cannabis products from Canada, first to Germany and now to Switzerland. We have gained regulatory expertise to build a clear path for further exports as the Western European market develops”, said Ben Ward, CEO of Wayland. “Further, our products are within a stability range from which we can formulate products reliably and consistently for the cannabis market, including pharmaceuticals, and recreational products. This means we can make dosage-controlled edibles, beverages, and topicals, in combination with our proprietary VesiSorb technology, in addition to our existing CBD capsules marketed under our Mariplant brand”.
Wayland is one of the first companies to successfully create a stable range of THC distillate in Canada. The distillate will undertake further analysis and tests in Switzerland to ensure conformance with local Swiss ordinance. An export permit was granted by Health Canada to Wayland’s contract service provider and import permit by SwissMedic to Wayland’s Swiss Pharmaceutical Partner.
Maricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details see the press release dated September 24, 2018.
About Wayland Group Corp.
Wayland is a vertically integrated producer and distributor of marijuana for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Wayland is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) footprint upon full buildout, and will continue to pursue new opportunities in Europe.